Furthermore, anti-proprotein convertase subtilisin/kexin9(PCSK9) aptamers have been generated using CE-SELEX, presenting efficient PCSK9 inhibition, which may be potential therapeutic agents for patients with hypercholesterolemia and CAD (Sattari et al., 2020). Here, PCSK9 is linked to familial hypercholesterolemia.